<unk>  is contraindicated for people with a history of stroke, transient ischemic attack, or intracerebral hemorrhage. In studies of<unk>  on persons with prior ischemic stroke, there was an increased risk of intracranial hemorrhage without an improvement in major vascular events.<unk>  possesses a long half life which is a problem because there is currently no treatment to reverse the antiplatelet effects of<unk> . Because of this, it is important that<unk>  not be used in persons with history of stroke, transient ischemic attack, or intracranial hemorrhage, or active pathological bleeding. This family of medication, PAR-1 antagonists in general has been associated with an increased risk of intracranial bleeding demonstrated by a pooled analysis of data that studied 42000 patients with history of thrombotic vascular disease or acute coronary syndrome comparing the medication and a placebo.
Vorapaxar
Sesquimustard
Pretomanid
Vagisil
Tezacaftor
Patiromer
Tasimelteon
Enarodustat